BackSummary
Ascentage Pharma will present 17 clinical advances, including 8 posters, at the 2026 EHA Congress, highlighting olverembatinib and lisaftoclax data.
Key takeaways
- 17 clinical advances of core assets will be featured at EHA2026, including 8 poster presentations.
- Data includes olverembatinib (third-gen BCR-ABL inhibitor) and lisaftoclax (Bcl-2 inhibitor) studies.
- Key abstracts cover olverembatinib in CML and Ph+ ALL, and lisaftoclax in CLL/SLL.
- Both drugs are under investigation and not yet FDA-approved in the US.
- The EHA Congress is a major hematology meeting, enhancing visibility for Ascentage's pipeline.